Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
Press Release: Diabetic foot ulcers therapeutics market expected to maintain a moderate growth
The diabetic foot ulcers therapeutics market is expected to maintain a moderate growth over the coming years, having increased from a market value of £1.13 billion in 2006, to reach $1.53 billion by 2011. By 2019 it is predicted that the diabetic foot ulcers market will continue this growth and will hit a market value of $1.97 billion.
Diabetic foot ulcers can drastically impair quality of life and are a cause of significant morbidity, accounting for 20% of all diabetes-related hospital admissions in the US.
The diabetic foot ulcers market is made up of the diabetic foot infection (DFI) and wound healing sectors, with the two experiencing differing fortunes within the market.
On one hand the diabetic foot infection market experienced a positive growth, climbing from $1 billion to reach $1.6 billion, but the wound healing sector experienced a very different fate.
The wound healing market dropped from $126.5m in 2006, to $73.8m in 2011, dropping at a negative compound annual growth rate (CAGR) of 10.2%. This market decline can be attributed to the fact that the US Food and Drugs Administration (FDA) slapped a 'black box' warning on their only product, Regranex, due to concerns that large quantities could increase the risk of cancer by up to five times.
None the less, the DFI sector was also not without its woes. The three major drugs in this area all have side effect issues. Given the problems with these current treatments, it appears there are opportunities for new drugs to push through and make an impression on the diabetic foot ulcers therapeutics market.
Global Markets Direct's, 'Diabetic Foot Ulcers - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers.
- A snapshot of the global therapeutic scenario for Diabetic Foot Ulcers.
- A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Foot Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- News and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.